Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Net Income (2023 - 2025)

Historic Net Income for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.

  • CG Oncology's Net Income fell 11422.34% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 10798.61%. This contributed to the annual value of -$88.0 million for FY2024, which is 8136.16% down from last year.
  • Latest data reveals that CG Oncology reported Net Income of -$43.7 million as of Q3 2025, which was down 11422.34% from -$41.4 million recorded in Q2 2025.
  • CG Oncology's Net Income's 5-year high stood at -$8.7 million during Q1 2023, with a 5-year trough of -$43.7 million in Q3 2025.
  • In the last 3 years, CG Oncology's Net Income had a median value of -$18.9 million in 2024 and averaged -$23.3 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 6365.21% in 2024, then plummeted by 11904.81% in 2025.
  • CG Oncology's Net Income (Quarter) stood at -$16.6 million in 2023, then tumbled by 92.16% to -$31.8 million in 2024, then tumbled by 37.43% to -$43.7 million in 2025.
  • Its Net Income stands at -$43.7 million for Q3 2025, versus -$41.4 million for Q2 2025 and -$34.5 million for Q1 2025.